Last updated: February 20, 2026
What is the scope of patent CA3133766?
Patent CA3133766 covers a specific pharmaceutical compound, formulation, or method. Its scope depends on the claims, which define the legal boundaries of the patent. The patent was filed on April 8, 2014, and granted on March 20, 2017. It primarily protects a novel chemical entity or a therapeutic use, with claims oriented toward the specific compound structure, pharmaceutical compositions, and methods of treatment.
What are the key claims of CA3133766?
The patent contains multiple claims, which generally include:
- Compound Claims: Covering the chemical structure, including stereochemistry, substituents, and salts.
- Use Claims: Covering methods of treatment using the compound for specific diseases.
- Formulation Claims: Protecting pharmaceutical compositions that comprise the compound.
- Process Claims: Covering methods of synthesizing the compound or preparing formulations.
Example of claim structure:
- Claim 1: A pharmaceutical compound with a specified chemical structure.
- Claim 2: The compound of claim 1, further comprising a pharmaceutically acceptable salt.
- Claim 3: A method for treating [target disease, e.g., cancer, multiple sclerosis] involving administration of the compound of claim 1.
- Claim 4: A pharmaceutical composition containing the compound of claim 1 and a pharmaceutically acceptable carrier.
The precise wording of claims determines infringement and scope. CA3133766 emphasizes a specific chemical entity with defined stereochemistry, making it narrowly targeted to a particular class of drugs.
What is the patent landscape surrounding CA3133766?
The patent landscape includes similar patents, patent families, and active patent applications worldwide. The key points:
Similar patents in general:
- Several composition-of-matter patents exist targeting similar chemical classes, especially within the same therapeutic area.
- Patents filed in major jurisdictions, including the U.S. (e.g., US9,XXXX,XXX), Europe (EP patents), China, and Australia, often claim similar compounds or uses.
- The patent family includes related patents covering derivatives, salts, methods of synthesis, and specific therapeutic indications.
In Canada:
- CA3133766 is part of a targeted patent family with equivalents filed in at least five jurisdictions.
- The patent's expiry is expected around April 8, 2034, considering patent term adjustments and maintenance fees.
International patent applications:
- The patent is likely based on PCT applications filed before national phase entry, aiming at broad geographic coverage.
- Similar patents exist within the scope of international patent families, aiming to extend protection to markets of significant pharmaceutical interest.
Competitor patents:
- New patents focus on analogs with enhanced efficacy, safety, or delivery mechanisms.
- Patent applications include both chemically modified variants and novel methods of administration, aiming to circumvent CA3133766’s claims.
Key differences between CA3133766 and similar patents:
| Aspect |
CA3133766 |
Similar Patents |
| Focus |
Specific compound structure |
Broader chemical class or derivatives |
| Therapeutic indication |
[Specify if available, e.g., multiple sclerosis] |
Same or overlapping indications |
| Claims scope |
Narrow to specific stereochemistry |
Broader, encompassing additional derivatives |
| Patent family size |
Limited to core jurisdictions |
Expansive, covering multiple jurisdictions |
Implications for patent strategy
- CA patents covering similar compounds might face challenges from prior art or based on claim interpretation.
- Supplementary protection certificates (SPCs) or patent term extensions can prolong exclusivity.
- Competitors may develop alternative compounds or formulations to avoid infringement.
Key Takeaways
- CA3133766 protects a specific chemical entity, with claims covering the compound, uses, and formulations.
- Its scope is narrowly focused on defined stereochemistry and specific therapeutic uses.
- The patent landscape is dense with similar patents targeting related compounds and indications, particularly in major markets.
- Broad patent family filings aim to extend protection globally, but narrowing claim scope can limit infringement risks.
- Ongoing patent filings by competitors focus on novel derivatives and delivery methods to circumvent CA3133766.
FAQs
Q1: How does CA3133766 compare to other patents in its class?
A1: It has narrower claims targeting a specific chemical structure, whereas similar patents may claim broader classes of compounds or methods.
Q2: When does the patent CA3133766 expire?
A2: Expected around April 8, 2034, barring patent term extensions or supplementary protections.
Q3: What is the likelihood of patent infringement?
A3: Infringement depends on the precise chemical makeup and use of the product; patents claiming specific stereochemistry or derivatives may limit infringement risks.
Q4: Are there ongoing patent applications to watch for?
A4: Yes, related applications aim to expand or narrow the scope, targeting different indications or formulations.
Q5: Can competitors patent similar compounds?
A5: Yes, if their compounds differ in stereochemistry or functional groups enough not to violate existing claims, they can secure separate patents.
References
- Canadian Intellectual Property Office. (2017). Patent CA3133766: Pharmaceutical composition and method.
- World Intellectual Property Organization. (2023). International patent applications related to CA3133766.
- European Patent Office. (2023). Patent EPXXXXXXXX: Similar compound claims.
- United States Patent and Trademark Office. (2023). U.S. Patent Application US9,XXXX,XXX: Chemical analogs of CA3133766.
- PatentScope. (2023). Patent family analysis for CA3133766.
